REMAP-CAP Podcast Series
Don’t miss REMAP-CAP’s informative podcast series. With nine episodes and counting, dive into the design, obtained results and publications of this trial together with Critical Care Reviews’ Rob Mac Sweeney and several REMAP-CAP family members.
At REMAP-CAP, we believe it is crucial to communicate the work being done by our global family.
REMAP-CAP Podcasts
Here’s an overview of our episodes to date:
Episode #1 – Senior investigators Derek Angus and Tony Gordon discuss the corticosteroids manuscript published in JAMA and put these results into context.
Episode #2 – Prof. Steve Webb on the rationale and origin design of REMAP-CAP.
Episode #3 – Dr. Scott Berry explains REMAP-CAP’s statistical plan.
Episode #4 – Prof. John Marshall and assistant professor Srinivas Murthy about REMAP-CAP’s intervention menu.
Episode #5 – Prof. Mathias Pletz about pandemics and REMAP-CAP’s COVID-19 pandemic mode.
Episode #6 – Prof. Alistair Nichol on REMAP-CAP’s Ventilation domain.
Episode #7 – Prof. Derek Angus on the interaction between clinical research and clinical practice. He discusses the concept of a learning healthcare system and how this relates to the REMAP-CAP trial.
Episode #8 – Dr. Lennie Derde talks about her background in critical care, infectious diseases, and research, noting all of the output generated by REMAP-CAP to date. Plus, Lennie gives her view on how this pandemic is likely to progress.
Episode #9 – Prof. Alistair Nichol about ivermectin, one of the latest interventions added to the REMAP-CAP trial. He explains why this intervention is being implemented despite the controversy surrounding the use of ivermectin to treat COVID-19.
Are you part of the #remapcapfamily, soon to be or just eager to learn more about adaptive platform trials? Listen to REMAP-CAP’s podcast series on Spotify and iTunes.
REMAP-CAP
A lot has happened within the REMAP-CAP trial this past year. With the ability to improve the trial design according to new insights with a clinical trial infrastructure already in place, REMAP-CAP has easily extended its domains since the beginning of 2020 to investigate new treatments specifically for COVID-19 patients. Furthermore, the #remapcapfamily has grown exponentially to 340 active sites globally with several domains and interventions added to the trial, not to mention numerous publications. At REMAP-CAP, we believe it is crucial to communicate the work being done by our global family and to share insights into the different fields of patient care, research, and study management in REMAP-CAP.
For the latest be sure to follow REMAP-CAP Twitter, Linkedin, and Instagram.